Lupin Limited (BOM:500257)
1,969.50
-17.80 (-0.90%)
At close: May 27, 2025
Lupin Revenue
In the fiscal year ending March 31, 2025, Lupin had annual revenue of 227.08B INR with 13.48% growth. Lupin had revenue of 56.67B in the quarter ending March 31, 2025, with 14.24% growth.
Revenue
227.08B
Revenue Growth
+13.48%
P/S Ratio
3.91
Revenue / Employee
11.82M
Employees
19,210
Market Cap
886.77B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 227.08B | 26.97B | 13.48% |
Mar 31, 2024 | 200.11B | 33.69B | 20.25% |
Mar 31, 2023 | 166.42B | 2.36B | 1.44% |
Mar 31, 2022 | 164.05B | 12.43B | 8.19% |
Mar 31, 2021 | 151.63B | -2.12B | -1.38% |
Mar 31, 2020 | Pro | Pro | Pro |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Reliance Industries | 9,646.93B |
HDFC Bank | 2,728.47B |
Tata Consultancy Services | 2,553.24B |
Bharti Airtel | 1,729.85B |
ICICI Bank | 2,006.54B |
State Bank of India | 3,155.91B |
Infosys | 1,647.16B |
Bajaj Finance | 369.88B |
Lupin News
- 13 days ago - Lupin secures FDA approval for Rivaroxaban 10 mg, 15 mg and 20 mg tablets - Business Upturn
- 15 days ago - Lupin launches Tolvaptan tablets in the US for ADPKD treatment - Business Upturn
- 21 days ago - Lupin launches Eslicarbazepine Acetate Tablets in the US - Business Upturn
- 4 weeks ago - Lupin extends slump sale of API R&D and OTC business to June 30, 2025 - Business Upturn
- 4 weeks ago - Lupin receives U.S. FDA approval for Tolvaptan tablets with 180-day exclusivity - Business Upturn
- 5 weeks ago - Lupin receives EIR from US FDA for its injectable manufacturing facility in Nagpur - Business Upturn
- 6 weeks ago - Lupin shares tumble nearly 3% after US court setback in Myrbetriq patent case - Business Upturn
- 7 weeks ago - Lupin: Business Model, Q3 FY25 Earnings, Promoter Details, and Shareholding Pattern - Business Upturn